FLC
SABS icon

Fifth Lane Capital’s SAB Biotherapeutics SABS Stock Holding History

Fifth Lane Capital’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$178K Buy
46,500
+31,500
+210% +$126K 0.22% 47
2025
Q4 		$56.1K Buy
+15,000
New +$49.4K 0.04% 100

Other funds holding SABS

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fifth Lane Capital's SABS Position: Q1 2026 in Review

Fifth Lane Capital increased its SAB Biotherapeutics (SABS) stake by 210% in Q1 2026, buying an estimated $126K and bringing the position to 46,500 shares worth $178K. The position accounts for 0.22% of the portfolio, ranked #47.

Fifth Lane Capital first reported a position in SABS in Q4 2025 and has held it in 2 quarters since. 76 funds tracked by Wall St. Rank hold SABS as of Q1 2026.

  • Fifth Lane Capital held 46,500 shares of SAB Biotherapeutics worth $178K as of Q1 2026.
  • Fifth Lane Capital bought 31,500 SAB Biotherapeutics shares in Q1 2026, an estimated $126K.
  • SAB Biotherapeutics made up 0.22% of Fifth Lane Capital's portfolio in Q1 2026, its #47 holding.
  • Fifth Lane Capital first reported a position in SAB Biotherapeutics in Q4 2025 and has held it in 2 quarters since.
  • 76 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q1 2026.

Based on Fifth Lane Capital's 13F filing for Q1 2026, filed 15 May 2026.